Sister chromatid differentiation and cell‐cycle‐specific patterns in chronic myelocytic leukemia and normal bone marrow

Becher, R.; Schmidt, C. G.

doi:10.1002/ijc.2910290603

Cited by 10 publications

(3 citation statements)

References 13 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further more, this study design allows an investigation of proliferation-inhibiting effects through an analysis of cell cycle specific SCD patterns. Cell cycle studies utilizing the SCD technique have been shown to be an accurate and easy method for proliferation studies [9]. In the studies presented, mesna, a drug being used increasingly in clinical practice to limit the urotoxic effects of oxazaphosphorine derivatives, has been shown not to interact with chromosomal DNA, with regard to the induction of structural chromosomal aberrations or increased SCE frequencies; further more, it apparently does not interfere with cell proliferation.…”

Section: Discussionmentioning

confidence: 99%

Cytogenetic Testing of Mutagenic and Radioprotective Effects of Mesna

Becher¹,

Kakati²,

Gibas³

et al. 1983

Oncology

Self Cite

View full text Add to dashboard Cite

The effects of mesna (sodium 2-mercaptoethane-sulfonate) on the frequency of sister chromatid exchange (SCE) and chromosomal aberrations were studied in PHA-stimulated lymphocytes in vitro. Our data give no evidence for either an increase of SCE or chromosomal aberrations and, thus, do not suggest a mutagenic or cancerogenic potential of this drug, when used clinically for the reduction of urotoxicity caused by oxazaphosphorine derivatives in cancer therapy. The possibility of a radioprotective effect of mesna could not be supported by the results obtained in this test system. However, there remained a slight comutagenic effect of mesna, if used together with irradiation, which should be taken into account when this drug is administered in the preparation of patients for bone marrow transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%

Cytogenetic Testing of Mutagenic and Radioprotective Effects of Mesna

Becher¹,

Kakati²,

Gibas³

et al. 1983

Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…These results confirm our data based upon cytological observation, and strongly suggest that only one half of the first S-phase is in fact required for Rat-1 cells to demonstrate differential chromosome staining. These results may be of importance to studies of cellular proliferation which use BrdU incorporation because many in vitro studies have estimated cell GT, based upon the assumption that cells exposed to continuous BrdU labelling pass through two complete S-phases before showing complete differential staining (Tice, Schneider & Rary, 1976;Crossen & Morgan, 1977a;Craig-Holmes & Shaw, 1976;Becher & Schmidt, 1982). Because of the relative insensitivity of the FPG method in measuring early S-phase BrdU incorporation (Tice et al, 1979;this report), studies which assess the time of first appearance of second division cells can be expected to overestimate the GT (Trent el al., 1986).…”

Section: R E S U L T S a N D Discussionmentioning

confidence: 99%

Analysis of the Length of S‐Phase Required to Show Sister Chromatid Differential Staining

et al. 1986

View full text Add to dashboard Cite

In uitro studies of BrdU-dependent sister chromatid differential staining typically employ two cycles of BrdU incorporation. Experiments are described which determined the actual fraction of both S-phases that the rat embryonic fibroblasts (Rat-1) cells had to traverse in order to show distinctive differential staining. Following synchronization of cells by a combination of serum deprivation and hydroxyurea blockage, sister chromatid differential staining, labelling index, mitotic index, and per cent DNA replication are determined. Results indicate that only -50% of the first S-phase is necessary in order to show distinctive differential staining. The importance of this finding to studies of cellular proliferation using BrdU incorporation is discussed.Recent studies of cellular proliferation have utilized 5-bromodeoxyuridine (BrdU) incorporation followed by sister chromatid differential staining (Tice, Schneider ). This system is based on culturing cells in the presence of BrdU and the subsequent identification of metaphases which have replicated for one, two or three cell cycles. It is known that exposure to BrdU for one S-phase (followed by a second S with or without BrdU) allows differential staining of sister chromatids. Most in vitro studies, however, utilize continuous BrdU labelling for both cell cycles (rather than washing out BrdU for the second cycle). In this report, we describe experiments which are designed to determine the actual fraction of both S-phases rat embryonic fibroblast (Rat-1) cells must traverse in order to show distinctive differential staining. M A T E R I A L S A N D M E T H O D S Cell cycle blockadeRat embryo fibroblast (Rat-1) cells were cultured at 39OC in McCoy's 5a medium supplemented with 10% fetal bovine serum and 1 % penicillin-streptomycin. Under these conditions, Rat-I cells were determined to have the following cell cycle parameters: generation time

show abstract

“…The cell cycle specific pattern of sister chromatid differentiation (SCD) was studied by evaluation of M0/1. M2, and M3 metaphases which were defined according to the number of S phases during which BrdU was incorporated [8]. If possible, at least 25 metaphases were scored for SCE frequency and more than 100 metaphases for cell cycle specific patterns.…”

Section: Sc E Studiesmentioning

confidence: 99%

No Effect of High-Dose Medroxyprogesterone Acetate on the Frequency of Sister Chromatid Exchange in Lymphocytes of Cancer Patients

Becher¹

1988

Oncology

Self Cite

View full text Add to dashboard Cite

Sister chromatid exchange observed in metaphase chromosomes has been shown to be a sensitive assay for the detection of possible mutagenic and/or carcinogenic agents. The semisynthetic progestin medroxyprogesterone acetate is a drug used in high doses for the treatment of advanced breast cancer. We studied the frequency of sister chromatid exchange in PHA-stimulated peripheral lymphocytes of 11 patients who received medroxyprogesterone acetate in high doses. Overall results disclosed no significant effect of this drug on the frequency of sister chromatid exchange (SCE) and cell proliferation in sister chromatid differentiation patterns. Considering sex differences a slight tendency towards SCE increase and growth delay was observed in females.

show abstract

Sister chromatid differentiation and cell‐cycle‐specific patterns in chronic myelocytic leukemia and normal bone marrow

Cited by 10 publications

References 13 publications

Cytogenetic Testing of Mutagenic and Radioprotective Effects of Mesna

Cytogenetic Testing of Mutagenic and Radioprotective Effects of Mesna

Analysis of the Length of S‐Phase Required to Show Sister Chromatid Differential Staining

No Effect of High-Dose Medroxyprogesterone Acetate on the Frequency of Sister Chromatid Exchange in Lymphocytes of Cancer Patients

Contact Info

Product

Resources

About